Olprinone: A Phosphodiesterase III Inhibitor with Positive Inotropic and Vasodilator Effects

ABSTRACT Olprinone is a newly developed phosphodiesterase III inhibitor characterized by several properties. First, olprinone has positive inotropic and vasodilator actions and improves myocardial mechanical efficiency. Second, olprinone augments cerebral blood flow by a direct vasodilatory effect o...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular drug reviews 2002-09, Vol.20 (3), p.163-174
Main Authors: Mizushige, Katsufumi, Ueda, Takashi, Yukiiri, Kazushi, Suzuki, Hitoshi
Format: Article
Language:English
Subjects:
Antianginal agents. Coronary vasodilator agents
Biological and medical sciences
Cardiovascular system
Carotid Arteries - drug effects
Cerebral blood flow
Cerebrovascular Circulation - drug effects
Heart failure
Heart Failure - drug therapy
Humans
Imidazoles - pharmacology
Imidazoles - therapeutic use
Medical sciences
Muscle, Smooth, Vascular - drug effects
Myocardial Contraction - drug effects
Olprinone
Pharmacology. Drug treatments
Phosphodiesterase III inhibitor
Phosphodiesterase Inhibitors - pharmacology
Phosphodiesterase Inhibitors - therapeutic use
Positive inotropism
Pyridones - pharmacology
Pyridones - therapeutic use
Treatment Outcome
Vasodilatation
Vasodilation - drug effects
Vasodilator agents. Cerebral vasodilators
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Olprinone is a newly developed phosphodiesterase III inhibitor characterized by several properties. First, olprinone has positive inotropic and vasodilator actions and improves myocardial mechanical efficiency. Second, olprinone augments cerebral blood flow by a direct vasodilatory effect on cerebral arteries. The cerebrovascular reactivity to olprinone is marked in patients with impaired cerebral circulation. Third, olprinone selectively improves carotid artery distensibility, which may be attributable to differences in the arterial structural components or the reactivity of smooth muscle cells to olprinone. Fourth, olprinone improves inadequate redistribution of brain perfusion and may prevent cerebral metabolic abnormalities in heart failure.
ISSN:0897-5957
1527-3466
DOI:10.1111/j.1527-3466.2002.tb00085.x